Breaking News Instant updates and real-time market news.

ROKU

Roku

$160.41

-1.2 (-0.74%)

06:09
12/02/19
12/02
06:09
12/02/19
06:09

Morgan Stanley downgrades Roku to Underweight after 400% year-to-date rally

Morgan Stanley analyst Benjamin Swinburne downgraded Roku to Underweight from Equal Weight with a price target of $110, up from $100. The shares closed Friday down $1.27 to $160.37. Roku continues to execute a "sound strategy" to capitalize on the shift to streaming, but there are risks to growth expectations not reflected in current valuation levels, Swinburne tells investors in a research note. Specifically, he thinks the company's revenue and gross profit growth could slow "meaningfully" in 2020, leading to multiple compression. Swinburne is bullish on Roku's growth prospects, but he notes the shares are up over 400% year-to-date due to rising estimates and overall exuberance over all things streaming. As a result, the stock's risk/reward is skewed to the downside, contends the analyst. He points out that Roku's valuation levels have surged past digital media players and even past high-growth software-as-a-service companies.

ROKU Roku
$160.41

-1.2 (-0.74%)

11/07/19
RBCM
11/07/19
NO CHANGE
Target $160
RBCM
Outperform
Roku price target raised to $160 from $155 at RBC Capital
RBC Capital analyst Mark Mahaney raised his price target on Roku to $160 and kept his Outperform rating after its Q3 results. The analyst notes that the quarter was mixed with a "much smaller" revenue beat than in prior two quarters while EBITDA guidance missed expectations given the company's plans to continue its aggressive investments in R&D and headcount. Mahaney still believes however that Roku is one of the best plays on ad-supported over-the-top market, as it is positioned to take share of the very large, underpenetrated $70B TV Ad spend opportunity.
11/07/19
GUGG
11/07/19
NO CHANGE
Target $150
GUGG
Buy
Roku price target lowered to $150 from $170 at Guggenheim
Guggenheim analyst Michael Morris lowered his price target on Roku shares to $150 from $170 after the company reported strong unit and revenue growth trends in both its Platform and Product segments in the third quarter but posted active account growth that was below consensus and had outperformance that "lagged historical beats." Also, Roku's guidance ex-acquisitions implies slower growth than he had anticipated, said Morris, who keeps a Buy rating on the stock but lowered his multi-year gross profit estimates by about 10%.
11/15/19
BOFA
11/15/19
NO CHANGE
Target $160
BOFA
Buy
Roku price target raised to $160 from $150 at BofA/Merrill
BofA/Merrill analyst Ziv Israel noted that Roku (ROKU) announced a variety of Black Friday offers and discounts on Roku streaming devices, content promotions, and the temporary availability of the Roku SE streaming player exclusively at Walmart (WMT). The company also announced three new smart TV models sold under the Walmart house brand that he estimates are currently priced at about half of TVs with similar attributes. The lower device average selling prices and new smart TV offerings provide a "solid setup for outsized Q4 account growth," contends Israel, who reiterates a Buy rating and raised his price target to $160 on Roku shares.
12/02/19
MSCO
12/02/19
DOWNGRADE
Target $110
MSCO
Underweight
Roku downgraded to Underweight from Equal Weight at Morgan Stanley
Morgan Stanley analyst Benjamin Swinburne downgraded Roku to Underweight from Equal Weight with a $110 price target.

TODAY'S FREE FLY STORIES

VRTX

Vertex

$220.43

0.37 (0.17%)

, REGN

Regeneron

$372.10

-1.41 (-0.38%)

05:39
12/13/19
12/13
05:39
12/13/19
05:39
Recommendations
Vertex, Regeneron analyst commentary  »

Credit Suisse replaces…

VRTX

Vertex

$220.43

0.37 (0.17%)

REGN

Regeneron

$372.10

-1.41 (-0.38%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Mar

OPI

Office Properties

$32.93

-1.02 (-3.00%)

05:36
12/13/19
12/13
05:36
12/13/19
05:36
Downgrade
Office Properties rating change  »

Office Properties…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VOLVY

Volvo

$0.00

(0.00%)

05:36
12/13/19
12/13
05:36
12/13/19
05:36
Hot Stocks
Volvo appoints Scott Rafkin as Chief Digital Officer »

Scott Rafkin, currently…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AMGN

Amgen

$236.18

2.22 (0.95%)

05:36
12/13/19
12/13
05:36
12/13/19
05:36
Recommendations
Amgen analyst commentary  »

Amgen price target raised…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NDSN

Nordson

$162.94

-4.5 (-2.69%)

05:36
12/13/19
12/13
05:36
12/13/19
05:36
Upgrade
Nordson rating change  »

Nordson upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NBIX

Neurocrine

$111.41

-1.85 (-1.63%)

05:35
12/13/19
12/13
05:35
12/13/19
05:35
Downgrade
Neurocrine rating change  »

Neurocrine downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NDSN

Nordson

$162.94

-4.5 (-2.69%)

05:35
12/13/19
12/13
05:35
12/13/19
05:35
Downgrade
Nordson rating change  »

Nordson downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GLPG

Galapagos

$214.12

-0.74 (-0.34%)

05:33
12/13/19
12/13
05:33
12/13/19
05:33
Downgrade
Galapagos rating change  »

Galapagos downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

GILD

Gilead

$67.64

0.5 (0.74%)

05:31
12/13/19
12/13
05:31
12/13/19
05:31
Downgrade
Gilead rating change  »

Gilead downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BIIB

Biogen

$293.92

1.71 (0.59%)

05:29
12/13/19
12/13
05:29
12/13/19
05:29
Upgrade
Biogen rating change  »

Biogen upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

REGN

Regeneron

$372.10

-1.41 (-0.38%)

05:26
12/13/19
12/13
05:26
12/13/19
05:26
Upgrade
Regeneron rating change  »

Regeneron upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RHHBY

Roche

$0.00

(0.00%)

, EXEL

Exelixis

$17.68

0.05 (0.28%)

05:25
12/13/19
12/13
05:25
12/13/19
05:25
Hot Stocks
Genentech says Phase III IMspire150 study met primary endpoint of PFS »

Genentech, a member of…

RHHBY

Roche

$0.00

(0.00%)

EXEL

Exelixis

$17.68

0.05 (0.28%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Dec

HTHT

Huazhu Group

$34.86

0.92 (2.71%)

05:23
12/13/19
12/13
05:23
12/13/19
05:23
Upgrade
Huazhu Group rating change  »

Huazhu Group upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RHHBY

Roche

$0.00

(0.00%)

05:22
12/13/19
12/13
05:22
12/13/19
05:22
Hot Stocks
Genentech says Phase III IMspire150 study met primary endpoint of PFS »

Genentech, a member of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Dec

SNAP

Snap

$14.45

0.22 (1.55%)

05:19
12/13/19
12/13
05:19
12/13/19
05:19
Upgrade
Snap upgraded to Outperform from Market Perform at JMP Securities »

JMP Securities analyst…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

INCY

Incyte

$92.79

-2.2 (-2.32%)

05:16
12/13/19
12/13
05:16
12/13/19
05:16
Recommendations
Incyte analyst commentary  »

Incyte risk/reward…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    May

PCG

PG&E

$11.75

-0.38 (-3.13%)

05:14
12/13/19
12/13
05:14
12/13/19
05:14
Hot Stocks
PG&E files amended plan of reorganization »

PG&E Corporation and…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Jan

SRPT

Sarepta

$100.39

-1.15 (-1.13%)

05:12
12/13/19
12/13
05:12
12/13/19
05:12
Recommendations
Sarepta price target raised to $210 from $185 at Piper Jaffray »

Piper Jaffray analyst…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LOVE

Lovesac

$11.81

-2.68 (-18.50%)

05:07
12/13/19
12/13
05:07
12/13/19
05:07
Downgrade
Lovesac rating change  »

Lovesac downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Dec

  • 19

    Dec

TDOC

Teladoc

$77.06

-0.36 (-0.46%)

05:04
12/13/19
12/13
05:04
12/13/19
05:04
Initiation
Teladoc initiated  »

Teladoc initiated with an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TTMI

TTM Technologies

$13.79

0.19 (1.40%)

05:01
12/13/19
12/13
05:01
12/13/19
05:01
Upgrade
TTM Technologies rating change  »

TTM Technologies upgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FII

Federated Investors

$34.41

0.41 (1.21%)

05:01
12/13/19
12/13
05:01
12/13/19
05:01
Downgrade
Federated Investors rating change  »

Federated Investors…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AMK

AssetMark Financial

$27.31

0.42 (1.56%)

05:00
12/13/19
12/13
05:00
12/13/19
05:00
Upgrade
AssetMark Financial rating change  »

AssetMark Financial…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VCTR

Victory Capital

$21.68

0.235 (1.10%)

05:00
12/13/19
12/13
05:00
12/13/19
05:00
Downgrade
Victory Capital rating change  »

Victory Capital…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EV

Eaton Vance

$47.08

0.395 (0.85%)

05:00
12/13/19
12/13
05:00
12/13/19
05:00
Upgrade
Eaton Vance rating change  »

Eaton Vance upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.